|
Online View
|
|
|
|
Harnessing ADAR Enzymes for
Targeted RNA Therapeutics
|
|
|
|
RNA editing, offering reversible, precise gene therapy without DNA modification risks, leverages A-to-I deamination (adenosine to inosine) via ADAR enzymes. ADAR-based therapies surpass CRISPR-Cas9 in specificity. SignalChem Biotech is proud to introduce its new recombinant human ADAR proteins: ADAR1 (p150), ADAR1 (p110), and ADAR2L (ADARB1), now with innovative in-house developed activity assays. These tools support research into ADAR’s functions and therapeutic strategies, including in vitro deamination assays to study RNA editing mechanisms, identify RNA targets, and screen potential modulators.
|
|
Find out More Details 
|
|
Why Choose SignalChem Biotech?
|
|
Library of 1500+ Active Enzyme
|
|
Activity Validation & High Purity
|
|
|
Rigorous QA/QC Testing
|
|
Over 20 Years of Expertise in Enzyme
|
|
|
Featured ADAR Products
|
|
Human ADAR1 (p150) Protein
(Cat#: A601-35H)
|
|
|
|
Recombinant human ADAR1(p150) protein showed dose-dependent adenosine deaminase activity towards double-stranded RNA in an ELISA experiment. In a deaminase reaction containing 10 ng/μL enzyme, a signal-to-background ratio of ≥4.77 was observed.
|
|
Human ADAR1 (p110) Protein
(Cat#: A611-35GH)
|
|
|
|
Recombinant human ADAR1(p110) protein showed dose-dependent adenosine deaminase activity towards double- stranded RNA in an ELISA experiment. In a deaminase reaction containing 4 ng/μL enzyme, a signal-to-background ratio of ≥5.16 was observed.
|
|
|
Human ADAR2L (ADARB1) Protein
(Cat#: A602-35F)
|
|
|
|
The purity of ADAR2L (ADARB1) was determined to be >85% by densitometry.
Observed MW ~100 kDa
Calculated MW ~85 kDa.
|
|
|
|
Recombinant human ADAR2L protein showed dose-dependent adenosine deaminase activity towards double-stranded RNA in an ELISA experiment. In a deaminase reaction containing 2 ng/μL enzyme, a signal-to-background ratio of ≥11.82 was observed.
|
|
|
Click to Learn More
|
|
|
|
|
|
|
|
Don’t Miss Out!
|
|
Kinase Drug Discovery Solutions >>
|
|
Center for Bioprocessing (C4B)
US-Based Recombinant Production >>
|
|
|
|
|
